MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare coverage and reimbursement. H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AARTI SHAH | — |
Health Issues HCR
340B-related issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
| Lobbyist | Covered position, as disclosed |
|---|---|
| AARTI SHAH | — |
Budget/Appropriations BUD
H. Con. Res. 112, Establishing the budget for the US Government for FY 2013. H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. H. J. Res. 117, Continuing Appropriations Resolutions, 2013.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AARTI SHAH | — |
Pharmacy PHA
Prescription Drug User Fee reauthorization. Product exclusivity issues; pedigree issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation). H.R. 5651, Food and Drug Administration Reform Act of 2012. S.2516, Food and Drug Administration Safety and Innovation Act. S.3187, Food and Drug Administration Safety and Innovation Act. S.2292, Patients' FDA Act. H.R. 6433, FDA User Fee Corrections Act of 2012.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AARTI SHAH | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.